TG Therapeutics Inc (NASDAQ:TGTX) Given Average Rating of “Buy” by Analysts

Shares of TG Therapeutics Inc (NASDAQ:TGTX) have been given an average rating of “Buy” by the nine analysts that are currently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $16.80.

TGTX has been the topic of a number of research reports. HC Wainwright set a $5.00 price objective on SuperCom and gave the company a “buy” rating in a report on Friday, April 12th. Zacks Investment Research cut Zymeworks from a “buy” rating to a “hold” rating in a report on Saturday, April 6th. BidaskClub raised Winmark from a “sell” rating to a “hold” rating in a report on Tuesday, May 14th. B. Riley reissued a “buy” rating on shares of TG Therapeutics in a report on Tuesday, June 11th. Finally, Cantor Fitzgerald initiated coverage on CytomX Therapeutics in a report on Monday, May 13th. They set an “overweight” rating and a $21.00 price objective on the stock.

In related news, CFO Sean A. Power sold 17,654 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $8.47, for a total transaction of $149,529.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael S. Weiss purchased 50,000 shares of TG Therapeutics stock in a transaction that occurred on Wednesday, June 26th. The shares were bought at an average price of $7.04 per share, for a total transaction of $352,000.00. The disclosure for this purchase can be found here. Company insiders own 14.20% of the company’s stock.



Institutional investors and hedge funds have recently bought and sold shares of the stock. Measured Wealth Private Client Group LLC purchased a new stake in TG Therapeutics during the first quarter valued at approximately $291,000. Raymond James & Associates raised its position in TG Therapeutics by 15.6% during the first quarter. Raymond James & Associates now owns 381,437 shares of the biopharmaceutical company’s stock valued at $3,067,000 after purchasing an additional 51,418 shares during the period. Raymond James Financial Services Advisors Inc. raised its position in TG Therapeutics by 14.7% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 164,479 shares of the biopharmaceutical company’s stock valued at $1,322,000 after purchasing an additional 21,139 shares during the period. BNP Paribas Arbitrage SA raised its position in TG Therapeutics by 239.6% during the first quarter. BNP Paribas Arbitrage SA now owns 13,117 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 9,255 shares during the period. Finally, Baldwin Brothers Inc. MA raised its position in TG Therapeutics by 67.2% during the first quarter. Baldwin Brothers Inc. MA now owns 29,850 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 12,000 shares during the period. Institutional investors and hedge funds own 54.60% of the company’s stock.

Shares of NASDAQ:TGTX traded up $0.04 on Friday, hitting $8.00. The company’s stock had a trading volume of 38,653 shares, compared to its average volume of 1,769,710. The firm’s 50-day moving average price is $7.50. TG Therapeutics has a 1 year low of $3.32 and a 1 year high of $13.60. The company has a quick ratio of 1.72, a current ratio of 1.72 and a debt-to-equity ratio of 1.89.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.01. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative return on equity of 309.17% and a negative net margin of 99,471.43%. On average, equities research analysts expect that TG Therapeutics will post -1.58 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Read More: Diluted Earnings Per Share

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.